PRTA Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Real Parkinson’s Disease Hope from Jupiter Neurosciences By Mike Sheikh Parkinson’s Disease has challenged drug developers for generations, but Jupiter Neurosciences (NASDAQ: JUNS) is betting that a streamlined clinical plan can break the stalemate. The market isn’t recognizing the story yet with its paltry market cap of $5.0M, and that disconnect has created a sizable opportunity for investors for a future rerating. […] The post Real Parkinson’s Disease Hope from Jupiter Neurosciences appeared first on ExecEdge. | ||
 KMDA or PRTA: Which Is the Better Value Stock Right Now? KMDA vs. PRTA: Which Stock Is the Better Value Option? | ||
 PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus Prothena beat adjusted Q2 loss estimates, reaffirmed 2026 cash-use guidance and highlights partner pipeline progress as a key milestone decision nears. | ||
 Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates Prothena (PRTA) delivered earnings and revenue surprises of +17.95% and -1.94%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates Vanda (VNDA) delivered earnings and revenue surprises of -103.92% and -19.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
PRTA Stock Rises Nearly 11% in Six Months: What's Driving It? Prothena shares climb as late-stage partnered programs advance, milestone payments strengthen finances and its neurodegenerative pipeline continues to expand. | ||